SUNDAY, JUNE 17, 2018

PaxVax COO adds 'president' to his title

PaxVax Chief Operating Officer Nima Farzan has been appointed president of the company, the firm said Wednesday.

PaxVax is a specialty vaccine company focused on travel and biodefense.

"PaxVax has built the industry’s most robust portfolio of commercial and late-stage vaccine candidates for compelling-yet-overlooked markets such as travel and biodefense," Farzan said. "I am very proud of what we have accomplished as a team and look forward to continuing to execute on our strategy to build the world’s leading specialty vaccine company."

Farzan has served as PaxVax's COO for the past three years and will now be responsible for the company’s global operations, including the finance, production and commercial functions. He also will join the PaxVax Board of Directors.

Kenneth Kelley will stay on as PaxVax's CEO and a board director.

"Nima has been instrumental in building PaxVax into a fully integrated commercial vaccine company with global sales and manufacturing capabilities," Kelley said. "Nima’s operational expertise will continue to play an important role as we expand our international markets for our typhoid vaccine Vivotif, as well as expand our U.S. and European product portfolio through marketing and distribution deals, and product launches from our internal pipeline over the next couple years."

Farzan joined PaxVax in February 2012 after spending more than seven years in a variety of roles at Novartis AG. He has an MBA from Harvard Business School and an undergraduate degree in human biology from Stanford University.